Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: The World Health Organization recommends vaccines for prevention and control of typhoid fever, especially where antimicrobial-resistant typhoid circulates. In 2018, the Navi Mumbai Municipal Corporation (NMMC) implemented a typhoid conjugate vaccine (TCV) campaign. The campaign targeted all children aged 9 months through 14 years within NMMC boundaries (approximately 320 000 children) over 2 vaccination phases. The phase 1 campaign occurred from 14 July 2018 through 25 August 2018 (71% coverage, approximately 113 420 children). We evaluated the phase 1 campaign's programmatic effectiveness in reducing typhoid cases at the community level.
METHODS: We established prospective, blood culture-based surveillance at 6 hospitals in Navi Mumbai and offered blood cultures to children who presented with fever ≥3 days. We used a cluster-randomized (by administrative boundary) test-negative design to estimate the effectiveness of the vaccination campaign on pediatric typhoid cases. We matched test-positive, culture-confirmed typhoid cases with up to 3 test-negative, culture-negative controls by age and date of blood culture and assessed community vaccine campaign phase as an exposure using conditional logistic regression.
RESULTS: Between 1 September 2018 and 31 March 2021, we identified 81 typhoid cases and matched these with 238 controls. Cases were 0.44 times as likely to live in vaccine campaign communities (programmatic effectiveness, 56%; 95% confidence interval [CI], 25% to 74%; P = .002). Cases aged ≥5 years were 0.37 times as likely (95% CI, .19 to .70; P = .002) and cases during the first year of surveillance were 0.30 times as likely (95% CI, .14 to .64; P = .002) to live in vaccine campaign communities.
CONCLUSIONS: Our findings support the use of TCV mass vaccination campaigns as effective population-based tools to combat typhoid fever.
| Errataetall: |
CommentIn: Clin Infect Dis. 2023 Jul 5;77(1):145-147. - PMID 36947122 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 77(2023), 1 vom: 05. Juli, Seite 138-144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoffman, Seth A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.07.2023 Date Revised 18.07.2023 published: Print CommentIn: Clin Infect Dis. 2023 Jul 5;77(1):145-147. - PMID 36947122 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad132 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35452383X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35452383X | ||
| 003 | DE-627 | ||
| 005 | 20231226062417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad132 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM35452383X | ||
| 035 | |a (NLM)36947143 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoffman, Seth A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Infect Dis. 2023 Jul 5;77(1):145-147. - PMID 36947122 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: The World Health Organization recommends vaccines for prevention and control of typhoid fever, especially where antimicrobial-resistant typhoid circulates. In 2018, the Navi Mumbai Municipal Corporation (NMMC) implemented a typhoid conjugate vaccine (TCV) campaign. The campaign targeted all children aged 9 months through 14 years within NMMC boundaries (approximately 320 000 children) over 2 vaccination phases. The phase 1 campaign occurred from 14 July 2018 through 25 August 2018 (71% coverage, approximately 113 420 children). We evaluated the phase 1 campaign's programmatic effectiveness in reducing typhoid cases at the community level | ||
| 520 | |a METHODS: We established prospective, blood culture-based surveillance at 6 hospitals in Navi Mumbai and offered blood cultures to children who presented with fever ≥3 days. We used a cluster-randomized (by administrative boundary) test-negative design to estimate the effectiveness of the vaccination campaign on pediatric typhoid cases. We matched test-positive, culture-confirmed typhoid cases with up to 3 test-negative, culture-negative controls by age and date of blood culture and assessed community vaccine campaign phase as an exposure using conditional logistic regression | ||
| 520 | |a RESULTS: Between 1 September 2018 and 31 March 2021, we identified 81 typhoid cases and matched these with 238 controls. Cases were 0.44 times as likely to live in vaccine campaign communities (programmatic effectiveness, 56%; 95% confidence interval [CI], 25% to 74%; P = .002). Cases aged ≥5 years were 0.37 times as likely (95% CI, .19 to .70; P = .002) and cases during the first year of surveillance were 0.30 times as likely (95% CI, .14 to .64; P = .002) to live in vaccine campaign communities | ||
| 520 | |a CONCLUSIONS: Our findings support the use of TCV mass vaccination campaigns as effective population-based tools to combat typhoid fever | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Salmonella Typhi | |
| 650 | 4 | |a India | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a typhoid fever | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a Typhoid-Paratyphoid Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Attenuated |2 NLM | |
| 650 | 7 | |a Vaccines, Conjugate |2 NLM | |
| 700 | 1 | |a LeBoa, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Date, Kashmira |e verfasserin |4 aut | |
| 700 | 1 | |a Haldar, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Harvey, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Shimpi, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a An, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chenhua |e verfasserin |4 aut | |
| 700 | 1 | |a Jayaprasad, Niniya |e verfasserin |4 aut | |
| 700 | 1 | |a Horng, Lily |e verfasserin |4 aut | |
| 700 | 1 | |a Fagerli, Kirsten |e verfasserin |4 aut | |
| 700 | 1 | |a Borhade, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Daruwalla, Savita |e verfasserin |4 aut | |
| 700 | 1 | |a Dharmapalan, Dhanya |e verfasserin |4 aut | |
| 700 | 1 | |a Gavhane, Jeetendra |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Shrikrishna |e verfasserin |4 aut | |
| 700 | 1 | |a Rai, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Rathod, Varsha |e verfasserin |4 aut | |
| 700 | 1 | |a Shetty, Keertana |e verfasserin |4 aut | |
| 700 | 1 | |a Warrier, Divyalatha S |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Chakraborty, Debjit |e verfasserin |4 aut | |
| 700 | 1 | |a Bahl, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Katkar, Arun |e verfasserin |4 aut | |
| 700 | 1 | |a Kunwar, Abhishek |e verfasserin |4 aut | |
| 700 | 1 | |a Yewale, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Jason R |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatnagar, Pankaj |e verfasserin |4 aut | |
| 700 | 1 | |a Dutta, Shanta |e verfasserin |4 aut | |
| 700 | 1 | |a Luby, Stephen P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 77(2023), 1 vom: 05. Juli, Seite 138-144 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2023 |g number:1 |g day:05 |g month:07 |g pages:138-144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad132 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2023 |e 1 |b 05 |c 07 |h 138-144 | ||